TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Baxter International ( (BAX) ) has shared an update.
On November 19, 2025, Baxter International Inc. announced the commencement of cash tender offers for its senior unsecured notes due in 2026 and 2027, with a total purchase price up to $300 million. This strategic financial maneuver is aimed at optimizing the company’s debt structure and could potentially impact its financial stability and market positioning.
The most recent analyst rating on (BAX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
Baxter International’s overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, including high leverage and negative profitability, which are reflected in its valuation metrics. Technical indicators suggest a bearish trend, further weighing on the stock’s outlook. While the earnings call provides some positive guidance, the overall risks and challenges overshadow potential growth opportunities.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International Inc. operates in the healthcare industry, focusing on medical products and services that are essential for hospitals and healthcare providers worldwide.
Average Trading Volume: 7,136,868
Technical Sentiment Signal: Sell
Current Market Cap: $9.13B
See more data about BAX stock on TipRanks’ Stock Analysis page.